GlassScriptPhysician profile
Miranda R Makulski
NPI 1164489316
$5,177.49
in general payments reported to CMS, 2019-2025
34 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $115 · 2021: $527 · 2022: $715 · 2023: $1,416 · 2024: $1,453 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,561.05 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $452.34 | 2019-2024 | |
| Pfizer INC. | $428.46 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $381.91 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $318.05 | 2019-2024 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.51 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $238.09 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $225.86 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Otsuka America Pharmaceutical, INC. | $165.88 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $109.46 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $103.11 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $90.75 | 2021 | |
| Horizon Therapeutics Plc | $90.05 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $89.25 | 2022-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $78.14 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $56.67 | 2019 | |
| Glaxosmithkline, LLC. | $53.69 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $49.00 | 2023 | |
| Astellas Pharma US INC | $41.96 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $41.44 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $41.30 | 2023 | Heplisav-B |
| Lundbeck LLC | $38.46 | 2024 | Rexulti |
| Dexcom, INC. | $36.71 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $29.68 | 2023 | |
| Genentech USA, INC. | $28.96 | 2024 | Xolair |
| Insulet Corporation | $23.31 | 2023 | Omnipod |
| Janssen Biotech, INC. | $22.95 | 2019 | |
| Abbott Laboratories | $21.19 | 2024 | Freestyle Libre 3 |
| Organon LLC | $19.95 | 2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $18.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.51 | 2022 | |
| Phadia US INC. | $15.37 | 2021 | |
| Fortovia Therapeutics, INC. | $13.83 | 2019 | |
| Bioventus LLC | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Makulski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.